Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy

Atherosclerosis

Volumn 150, Issue 1, 2000, Pages 217-224

  Islam, Kazi Nazrul ^a,b   O'Byrne, Dawn ^a,b   Devaraj, Sridevi ^a,b   Palmer, Biff ^b   Grundy, Scott M ^a,b   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Hemodialysis; Lipid peroxidation; Low density lipoprotein; Peritoneal dialysis; Renal failure; Tocopherol

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; UNSATURATED FATTY ACID;

ADULT; ARTERIOSCLEROSIS; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION REACTION; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ADULT; ANTIOXIDANTS; ARTERIOSCLEROSIS; FATTY ACIDS, UNSATURATED; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; LIPOPROTEINS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS; VITAMIN E;

EID: 0034183779     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00410-4     Document Type: Article

References (53)

1. Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance haemodialysis. Nephron 1998;80:380-400.
2. Ritz E, Gugustin J, Bommer J, Grasso A, Haberbosch W. Should hyperlipidemia of renal failure be treated? Kidney Int 1985;28(Suppl. 17):584-7.
3. Lindner A, Charra B, Sherrard D, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. New Engl J Med 1994;290:697-701.
4. Foley RN, Parfrey PS, Sarnak MJ. CAD in chronic renal disease: clinical epidemiology of CAD in chronic renal disease. Am J Kidney Dis 1998;32:S112-9.
5. Wanner C, Zimmerman J, Quaschning T, et al. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int 1997;52:S53-5.
6. Ron D, Oren I, Aviram M, et al. Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis 1983;46:67-75.
7. Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. New Engl J Med 1982;307:329-33.
8. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998;32:S142-56.
9. Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadaa L, Sherrard DJ. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977;26:903-7.
10. Senti M, Romero R, Pedro-Botert J, Pelegri A, Nogues X, Rubies-Part J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992;41:1394-9.
11. Jackson P, Loughrey CM, Lightbody JH, McNamee P, Young IS. Effect of haemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995;41:1135.
12. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee P, Trimble ER. Oxidative stress in hemodialysis. Q J Med 1994;87:679.
13. Westhuyzen J, Adama KE, Fleming SA. Evidence for oxidative stress during in vitro dialysis. Nephron 1995;70:49-54.
14. Dasgupta A, Hussain S, Ahmad S. Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992;60:56 9.
15. Daschner M, Lenhartz H, Botticher D, et al. Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996;50:1268-72.
16. Haklar G, Yegenaga I, Yalcin S. Evaluation of oxidant stress in chronic hemodialysis patients' use of different parameter. Clin Chim Acta 1992;234:1394-9.
17. McEneny J, Loughrey CM, McNamee PT, et al. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 1997;129:215-20.
18. Panzetta O, Cominacini L, Garbin U, et al. Increased susceptibility of LDL to in vitro oxidation in patents on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol 1995;44:303-9.
19. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-83.
20. Schulz T, Schiffl H, Scheithe R, Hrboticky N, Lorenz R. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am J Kidney Dis 1995;25:564-71.
21. Westhuyzen J, Saltissi D, Healy H. Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis 1997;129:199-205.
22. Loughrey CM, Young IS, McEneny J, et al. Oxidation of low density lipoprotein in patients on regular haemodialysis. Atherosclerosis 1994;110:185-93.
23. Sutherland WHF, Walker RJ, Ball MJ, et al. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995;48:227-36.
24. Parthasarathy S, Rankin SM. Role of oxidized LDL in atherogenesis. Prog Lipid Res 1992;92:127-43.
25. Jialal I, Fuller CJ. Effect of vitamin E, vitamin C and beta carotene on LDL oxidation and atherosclerosis. Can J Cardiol 1995;11:97G-109G.
26. Weber P, Benedich A, Machlin LJ. Vitamin E and Human Health: rationale for determining recommended intake levels. Nutrition 1997;13:450-60.
27. Rimm ER, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary artery disease in men. New Engl J Med 1993;328:1450-6.
28. Traber MG, Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr 1996;16:321-47.
29. Jialal I, Fuller CJ, Huet B. The effect of α-tocopherol supplementation on LDL oxidation: a dose response study. Atheroscler Thromb 1995;15:190-8.
30. Jiang ZY, Hunt JV, Wolf SP. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low-density lipoprotein. Anal Biochem 1992;202:384-9.
31. Regnstrom J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to LDL oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.
32. Cominacini L, Garbin U, Pastorino AM, Davoli A, et al. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 1993;99:63-70.
33. Devaraj S, Jialal I. Oxidized low density lipoprotein and atherosclerosis. Int J Clin Lab Res 1996;26:178-84.
34. Stephens MG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary artery disease:CHAOS. Lancet 1996;347:781-6.
35. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995;62:1381S-4S.
36. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998;81:13B-7B.
37. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense LDL to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
38. Tribble DL, Krauss RM, Lansberg MG, Thiel PM, van den Berg JJ. Greater oxidative susceptibility of surface monolayer in small dense LDL may contribute to difference in copper oxidation among LDL subfractions. J Lipid Res 1995;36:662-71.
39. Daerr WH, Windler ETE, Greten H. Peroxidative modification of very low density lipoproteins in chronic hemodialysis patients. Nephron 1993;63:230-1.
40. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Lastscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985;28:158-67.
41. Kuwahara L, Markert M, Wauters JP. Neutrophil oxygen radical production by dialysis membranes. Nephrol Dial Transplant 1988;3:661-5.
42. Yawata Y, howe R, Jacob H. Abnormal red cell metabolism causing hemolysis in uremia. Ann Intern Med 1973;79:362-7.
43. Giardini O, Taccone Galluci M, Lubrano R, et al. Evidence of red blood cell membrane lipid peroxidation in hemodialysis patients. Nephron 1984;36:235-7.
44. Peuchant E, Carbonneau MA, Dubourg L, et al. Lipid peroxidation in plasma and red blood cells of patients undergoing hemodialysis: vitamin A, E, and iron status. Free Radic Biol Med 1994;16:339-46.
45. Stein G, Richter G, Funfstuck R, Sperschneider H, Gunther K. Serum vitamin E levels in patients with chronic renal failure. Int J Artif Organs 1983;6:285-7.
46. Pastor MC, Sierra C, Bonal J, Teixido J. Serum and RBC AT in uremic patients: effects of HD vs PD. Am J Nephrol 1993;13:238-43.
47. Hultqvist M, Hegbrant J, NilsonThorell C, Lindhohn T, et al. Plasma concentrations of vit C, E and MDA during hemodialysis. Clin Nephrol 1997;47:37-46.
48. Yalcin AS, Yurtkuran M, Dilek K, Kilinc A, Taga Y, Emerk K. The effect of Vitamin E therapy on plasma and erythrocyte lipid peroxidation in chronic hemodialysis patients. Clin Chim Acta 1989;185:109-12.
49. Yukawa S, Hibino A, Maeda T, Mimura K, et al. Effect of AT on in vitro and in vivo metabolism of LDL in HD patients. Nephrol Dial Transplant 1995;10:S1-3.
50. Taccone Galluci M, Giardini O, Ausiello C, et al. AT supplementation in HD patients: effects on PBMC LPO and immune response. Clin Nephrol 1986;25:81-6.
51. Taccone Galluci M, Lubrano R, Del Principe D, et al. Platelet LPO in HD patients: effects of AT supplementation. Nephrol Dial Transplant 1989;4:975-8.
52. Cristol JP, Bosc JY, Badiou S, et al. Erythropoietin and oxidative stress in hemodialysis; beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997;12:2312-7.
53. Devaraj S, Adams-Huet B, Fuller CJ, Jialal I. Dose response comparison of RR-AT and all rac AT on LDL oxidation. Arterioscler Thromb Vasc Biol 1997;17:2273-9.